In addition to regulating HLA-E surface expression, bortezomib has also been shown to activate an anti-cancer NK cell response via upregulation of FAS and death receptor 5 (DR5) on leukaemia and colorectal cancer cell lines [119]. Here, TNFRSF10B is linked to leukemia.